

Special Issue

Recent Advances in Understanding Glaucoma Pathophysiology

Message from the Guest Editors

Glaucoma is an irreversible blinding disease that involves distinct optic nerve degeneration and retinal ganglion cell (RGC) death associated with corresponding visual field defects. Intraocular pressure and other non-IOP factors, such as vascular factors, have been addressed as possible causes for glaucomatous damage development and progression. Other possible mechanisms have been suggested, including autophagy, oxidative stress, mitochondrial dysfunction and neuroinflammation. However, there are still many mysteries to unravel to understand the complex pathophysiology of the disease's development and progression. The aim of the current Special Issue is to explore the recent advances in the field to better understand the complex mechanisms responsible for glaucomatous optic nerve damage and RGC death. We invite the submission of innovative research papers and review articles that discuss glaucoma pathophysiology.

Guest Editors

Dr. Si Hyung Lee

Department of Ophthalmology, Soonchunhyang University Hospital
Bucheon, Bucheon 170, Republic of Korea

Dr. Wungrak Choi

Department of Ophthalmology, Institute of Vision Research, Yonsei
University College of Medicine, Seoul 03722, Republic of Korea

Deadline for manuscript submissions

closed (30 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/158586

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).